Archives | Selexis SA

July 10, 2018

Symphogen A/S and Selexis Expand Relationship as Symphogen Advances its Monoclonal Antibody (mAb) Mixture Pipeline

June 12, 2018

ProMIS Neurosciences Initiates Manufacturing of PMN310, its Lead Therapeutic Antibody for Treatment of Alzheimer’s Disease

May 31, 2018

IAVI, Selexis SA and Collaborators Publish Study Highlighting Improved Approach for Generating Complex Proteins Required for Producing HIV Vaccines

May 17, 2018

Selexis Named One of the “Best Companies to Work for in Switzerland 2018”

May 07, 2018

Swiss Biotech Association Honors Selexis Among Its Inaugural Group of Swiss Biotech Success Stories

Selexis SA is a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, providing unparalleled proprietary technology and the highly-specialized expertise that is necessary to translate scientific innovation into life-saving medicines for patients. Selexis’ SUREtechnology Platform™ facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the bioproduction continuum, spanning discovery to commercialization. With more than 100 partners worldwide, 85 drug products in clinical development and three commercial products utilizing Selexis-generated cell lines, the Company has a history of empowering scientists and biopharmaceutical companies around the world to realize the full potential of their research.